IQVIA (NYSE:IQV) Cut to "Hold" at StockNews.com

IQVIA (NYSE:IQV - Get Free Report) was downgraded by StockNews.com from a "buy" rating to a "hold" rating in a research report issued on Friday.

Other analysts also recently issued reports about the company. The Goldman Sachs Group decreased their target price on IQVIA from $280.00 to $250.00 and set a "buy" rating on the stock in a research report on Friday, November 1st. Deutsche Bank Aktiengesellschaft lowered their price objective on shares of IQVIA from $270.00 to $265.00 and set a "buy" rating on the stock in a research note on Friday, November 1st. Jefferies Financial Group cut shares of IQVIA from a "buy" rating to a "hold" rating and cut their target price for the stock from $266.00 to $242.00 in a research report on Wednesday, July 24th. Barclays lowered their price target on shares of IQVIA from $260.00 to $255.00 and set an "overweight" rating on the stock in a research report on Friday, November 1st. Finally, Evercore ISI cut their price objective on IQVIA from $270.00 to $265.00 and set an "outperform" rating for the company in a research report on Tuesday, October 8th. Five analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, IQVIA has an average rating of "Moderate Buy" and a consensus target price of $259.13.

IQVIA Price Performance

IQVIA stock traded up $1.49 during mid-day trading on Friday, reaching $219.17. The company had a trading volume of 1,418,430 shares, compared to its average volume of 1,101,442. The stock's 50-day simple moving average is $231.00 and its 200-day simple moving average is $229.31. The company has a market capitalization of $39.78 billion, a P/E ratio of 28.76, a P/E/G ratio of 2.26 and a beta of 1.51. The company has a debt-to-equity ratio of 1.76, a current ratio of 0.81 and a quick ratio of 0.81. IQVIA has a 1 year low of $190.20 and a 1 year high of $261.73.

Insider Buying and Selling

In other news, insider Eric Sherbet sold 1,300 shares of IQVIA stock in a transaction dated Tuesday, August 27th. The stock was sold at an average price of $246.33, for a total value of $320,229.00. Following the transaction, the insider now directly owns 19,536 shares of the company's stock, valued at $4,812,302.88. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. Corporate insiders own 1.60% of the company's stock.

Institutional Trading of IQVIA

A number of institutional investors have recently added to or reduced their stakes in the business. PGGM Investments boosted its position in shares of IQVIA by 55.8% in the second quarter. PGGM Investments now owns 12,073 shares of the medical research company's stock worth $2,553,000 after buying an additional 4,326 shares during the period. SG Americas Securities LLC grew its position in IQVIA by 80.1% in the first quarter. SG Americas Securities LLC now owns 45,787 shares of the medical research company's stock valued at $11,579,000 after acquiring an additional 20,369 shares in the last quarter. Quadrature Capital Ltd acquired a new stake in IQVIA in the first quarter valued at approximately $3,365,000. Raymond James & Associates raised its stake in shares of IQVIA by 0.7% during the second quarter. Raymond James & Associates now owns 800,374 shares of the medical research company's stock valued at $169,231,000 after purchasing an additional 5,417 shares during the period. Finally, UniSuper Management Pty Ltd boosted its stake in shares of IQVIA by 253.0% in the first quarter. UniSuper Management Pty Ltd now owns 6,029 shares of the medical research company's stock valued at $1,525,000 after purchasing an additional 4,321 shares during the period. 89.62% of the stock is owned by hedge funds and other institutional investors.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.